Novo Nordisk A/S
Trump is unlikely to end Medicare drug price talks — here’s what that means for patients and pharma
President Donald Trump arrives in the Brady Press Briefing Room at the White House on Jan. 30, 2025 in Washington, DC. Oliver Contreras | Afp | Getty Images President Donald Trump likely won’t do away with a landmark process that allows Medicare to negotiate drug prices with manufacturers, even as he moves to erase Joe […]
Read More
Hims & Hers faces scrutiny from senators on Super Bowl ad that ‘risks misleading’ patients
Hims & Hers is facing scrutiny from lawmakers over an advertisement for its weight loss offerings that’s slated to run during the Super Bowl on Sunday. Sens. Dick Durbin, D-Ill., and Roger Marshall, R-Kan., wrote a letter to the U.S. Food and Drug Administration on Friday expressing concerns over an “upcoming advertisement” that “risks misleading […]
Read More
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Ore Huiying | Bloomberg | Getty Images Eli Lilly on Thursday said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a […]
Read More
Novo Nordisk CEO says he’s confident about Wegovy supply, next-generation weight loss drugs
It’s been a rocky few months for Novo Nordisk. Prescription data from IQVIA suggests Novo’s obesity drug Wegovy is losing ground to rival Zepbound from Eli Lilly. Wegovy’s potential successor, CagriSema, came up short of investor expectations in a closely watched Phase 3 trial. Novo’s stock has fallen more than 20% over the last year, […]
Read More
Stocks making the biggest moves midday: Alphabet, Apple, Uber, Nvidia and more
Check out the companies making headlines in midday trading. Alphabet — Shares sank nearly 8% after the Google parent reported fourth-quarter revenue of $96.47 billion, short of the $96.56 billion expected from analysts polled by LSEG. Alphabet also said it will invest $75 billion in 2025 as it expands its artificial-intelligence strategy, versus the $58.84 […]
Read More
Stocks making the biggest moves premarket: Apple, AMD, Uber, Alphabet, PDD and more
Check out the companies making headlines before the stock market open. Alphabet — The Google parent tumbled 7% after fourth-quarter revenue of $96.47 billion lagged the $96.56 billion estimated by analysts polled by LSEG. Alphabet also said it plans to invest $75 billion in 2025 as it expands its artificial-intelligence strategy, more than the $58.84 […]
Read More
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Medical bottles and syringe are seen with Novo Nordisk logo displayed on a screen in the background. Nurphoto | Nurphoto | Getty Images Shares of Novo Nordisk rose on Wednesday after the company reported better-than-expected net profit in the fourth quarter amid soaring demand for its Wegovy obesity drugs, but forecast a slight slowdown in […]
Read More
European markets open mixed ahead of more earnings reports; GSK up 6%
TotalEnergies posts 21% drop in annual profit French oil major TotalEnergies on Wednesday reported a sharp drop in full-year earnings, against a backdrop of lower crude prices and weak fuel demand. The oil and gas giant posted full-year 2024 adjusted net income of $18.3 billion, reflecting a 21% fall from $23.2 billion a year earlier. Analysts had expected TotalEnergies’ […]
Read More
Healthy Returns: Why people quit weight loss, diabetes drugs within one year
Packages of weight loss drugs Wegovy, Ozempic and Mounjaro. Picture Alliance | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Happy Tuesday! Most people quit a highly popular class of weight loss and […]
Read More
FDA approves Novo Nordisk’s Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
The Food and Drug Administration on Tuesday approved Novo Nordisk‘s Ozempic to treat chronic kidney disease in patients who also have Type 2 diabetes, expanding the use of the wildly popular injection in the U.S. The drug is already widely used and covered to treat Type 2 diabetes. The FDA’s decision means Ozempic can now […]
Read More